Research on detection methods of related substances and degradation products of the antitumor drug selpercatinib.

Journal: Frontiers in chemistry
Published Date: Jan 13, 2025

Abstract

BACKGROUND: Selpercatinib, a selective RET kinase inhibitor, is approved for treating various cancers with RET gene mutations such as RET-rearranged thyroid cancer and non-small cell lung cancer. The presence of process-related and degradation impurities in its active pharmaceutical ingredient (API) can significantly affect its safety and effectiveness. However, research on detecting these impurities is limited.

Authors

  • Jingjing Xiang
    Department of Pharmacy, Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), Nantong, China.
  • Liangliang Cai
    Department of Pharmacy, Affiliated Hospital of Nantong University, Nantong, China.
  • Qin Wang
    Department of Pharmacy, Affiliated Hospital of Nantong University, Nantong, China.
  • Yonghong Zhu
    Department of Pharmacy, Affiliated Nantong Hospital of Shanghai University (The Sixth People's Hospital of Nantong), Nantong, China.
  • Yong Han
    Department of Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals